Skip to main content

Table 4 Laboratory outcome measures for the placebo group presented as average [mean (SE)] changes from baseline for the time on active therapy (weeks 24 – 48) compared with the time on placebo (weeks 0–24). Baseline values are the average of weeks – 2 and 0 for 0 – 24 week analysis and the average of weeks 20 and 24 for 24 – 48 week analysis

From: Zidovudine plus lamivudine in Human T-Lymphotropic Virus type-I-associated myelopathy: a randomised trial

  Weeks 0–24 Weeks 24–48 P
HTLV-I proviral loada (log10 copies/105 PBMCs) +0.03 (0.10) -0.09 (0.08) 0.50
Total Lymphocytesb (106/L) +148.2 (58.0) -71.1 (63.1) 0.02
CD3 Lymphocytesb (106/L) +98.4 (63.4) +7.0 (39.2) 0.28
CD3b % +0.2 (2.8) +2.8 (2.0) 0.22
CD4b Lymphocytes (106/L) +32.6 (33.1) +30.4 (46.9) 0.97
CD4b % -1.2 (0.9) +3.6 (1.9) 0.08
CD8b Lymphocytes (106/L) +65.8 (31.3) -23.5 (13.7) 0.04
CD8b % +1.4 (1.2) -0.7 (1.1) 0.16
CD25a % -0.8 (1.8) -0.2 (1.3) 0.82
CD69a % +0.4 (1.3) -0.2 (3.0) 0.89
CD71a% -0.3 (1.0) +0.5 (1.3) 0.76
HLA-DR% -4.85 (4.0) +1.05 (2.3) 0.40
  1. a Data only available on n = 6 due to missing baseline data
  2. b Data only available on n = 7 due to missing baseline data